- Datum13.03.2025
- Uhrzeit08:00 - 17:00 Uhr
- Veranstalter
stock3
Heidelberg Pharma AG Aktie
Verkaufen
Kaufen
Heidelberg Pharma AG Chart
Heidelberg Pharma AG Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (XETRA)
0,38 %
Intraday
2,35 %
1 Woche
8,75 %
1 Monat
6,97 %
Seit Jahresbeginn
-17,92 %
1 Jahr
-47,64 %
3 Jahre
6,97 %
5 Jahre
-15,56 %
10 Jahre
Wikifolio
Passender Service zu Heidelberg Pharma AG
Webinar zu Heidelberg Pharma AG
Kursinformationen (XETRA)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)2,110-3,250
- Jahrestief / Hoch (€)2,150-2,890
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Heidelberg Pharma AG
Keine Dividenden verfügbar
Termine von Heidelberg Pharma AG
- Jul10Heidelberg Pharma AGQ2 2025 Earnings Release
Beschreibung
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
